Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

6.900 +0.140 (+2.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment. 
Via Benzinga
Topics Intellectual Property
News headline image
PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 ↗
PBYI stock results show that Puma Biotechnology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
News headline image
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
3 small-cap biotechs with potential breakthroughs in 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. 
Via MarketBeat
Topics Bankruptcy
News headline image
3 Strong Buy Stocks Under $5: January 2024 ↗
A strong buy rating carries weight which speculative investors may want to research in these strong buy stocks under $5. 
Via InvestorPlace
News headline image
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.